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Purpose: The baseline-observation-carried-forward (BOCF) approach is one method to 
handle missing data from early treatment discontinuation. We examined modifications of this 
approach, taking into consideration treatment-related and nontreatment-related reasons for 
discontinuation.
Methods: Two duloxetine chronic pain trials (placebo-controlled) were used to examine the 
impact of different analytical methods on study outcome. Reasons for discontinuation were 
categorized as treatment-related and nontreatment-related. Missing data in the primary efficacy 
outcome were handled using five statistical methods: mixed-model repeated measures (MMRM), 
last-observation-carried-forward (LOCF), BOCF, modified BOCF (mBOCF, discontinuation 
due to treatment-related reasons, ie, adverse events [AEs] or lack of efficacy), and aeBOCF 
(discontinuation due to AEs only).
Results: Duloxetine was superior to placebo on mean change from baseline in Brief Pain 
Inventory average pain rating, using MMRM (study 1, P = 0.004; study 2, P  0.001), LOCF 
(study 1, P = 0.019; study 2, P  0.001), BOCF (study 1, P = 0.019; study 2, P = 0.013), and 
mBOCF (study 1, P = 0.041; study 2, P = 0.005). Using aeBOCF, duloxetine was superior to 
placebo in study 2 (P = 0.005) and numerically better in study 1 (P = 0.075).
Conclusion: Due to the different assumptions made by various methods regarding accounting 
for missing data, the analytical methods chosen may influence the interpretation of study results. 
Consideration should be given to the effect of actual treatment outcomes from patients. Employ-
ing different statistical approaches such as sensitivity analyses may help to assess the robustness 
of the study results and provide a more accurate reflection of the treatment outcome.
Keywords: discontinuation, treatment-related, pain, statistical
Introduction
A clinical trial is conducted with the intent to treat and evaluate all patients enrolled 
in the study. One of the most common problems encountered during clinical trials is 
the evaluation of data from patients who are unable to complete the full schedule of 
the clinical trial or otherwise drop out of the study. There are many potential reasons 
why patients may drop out of clinical trials, including poor compliance, inconvenience, 
schedule conflicts, protocol violations, adverse events, death, early recovery, or other 
nontreatment-related causes which are often out of the investigator’s control. Nonethe-
less, any reason for dropping out from the trial results in data lost from these patients 
(drop-outs) and this could lead to a potential bias in the final study outcome. It is 
therefore important to accommodate drop-outs to appropriately analyze the outcome 
of the clinical trial. Patient Preference and Adherence 2010:4 12
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Various statistical methods have been used to handle 
missing data in clinical trials. One of these methods 
includes the last-observation-carried-forward (LOCF) 
approach, in which the last observed nonmissing value is 
used in place of the missing endpoint. However, this method 
can have drawbacks because it provides biased estimates 
of treatment effects and biased tests of the null hypothesis 
associated with no treatment effect.1 In addition, if there is 
equal drop-out in both the active and placebo arms, LOCF 
is liable to underestimate the treatment effect, and in cases 
of unequal drop-outs, the bias can be much larger in either 
direction.2 In addition, with the LOCF method, one has to 
assume that subjects’ measurement remains at the same 
level from the moment of dropout onward to the end of the 
trial. Another method, the mixed-model repeated-measures 
(MMRM) analyses, utilizes likelihood-based estimation, 
subject-specific effects and correlations between the 
repeated measurements.3 This method is considered to be 
more reliable when conducting a primary analysis, and is 
sometimes preferred over the simple imputation approaches 
using the last, or baseline-observation-carried-forward 
(BOCF) methods.4  The BOCF method is another approach 
used to handle patient drop-outs.5 The difference between 
the BOCF and LOCF method is that BOCF uses the base-
line observation, whereas LOCF uses the last observa-
tion in place of the missing endpoint. The BOCF method 
requires that the patient remain active in the trial in order 
to be evaluated for a response. In this method, if the patient 
drops out from the trial, the baseline observation is treated 
as the final response from the patient regardless of the 
reason the patient dropped out or the scores at the time of 
withdrawal. Regulatory agencies often suggest this method, 
that may seem to be more conservative, be used when 
evaluating clinical trials, where it is commonly assumed 
that a patient withdrew from the trial because of lack of 
benefit or treatment-emergent adverse events. However, 
there are various other reasons why patients withdraw from 
trials, as mentioned previously. Hence, when evaluating the 
outcome of a clinical trial, it would be prudent to take into 
consideration treatment-related and nontreatment-related 
reasons for dropout.
Using data from 2 clinical trials of duloxetine for the 
treatment of chronic pain, ie, chronic lower back pain 
(CLBP) (study 1),6 and chronic pain due to osteoarthritis 
(OA) of the knee (study 2),7 we investigated the underlying 
reasons for patient discontinuation from the trials and their 
roles in the BOCF approach, and propose examining modi-
fications of the BOCF approach to take into consideration 
treatment-related and nontreatment-related reasons for 
discontinuation.
Methods
This research was carried out in two 13-week, randomized, 
double-blind, placebo-controlled trials. Study 1 included male 
and female patients (duloxetine N = 115, placebo N = 121) 
who had a clinical diagnosis of CLBP. Study 2 included 
male and female patients 40 years (duloxetine N = 128, 
placebo N = 128) with OA of the knee. The patient charac-
teristics are comparable between the two studies. Detailed 
patient demographics and other information about the patient 
characteristics for each of the individual studies have been 
previously presented.6,7
The primary study objective of these clinical studies 
was to assess the efficacy of duloxetine, as compared with 
placebo, on the reduction of pain severity, as measured by the 
Brief Pain Inventory (BPI) 24-hour average pain rating.
Statistical analyses
Primary efficacy analysis in both studies was analysis of 
mean change from baseline in BPI average pain using an 
MMRM approach.
Both LOCF and BOCF were prespecified in the study 
protocols as additional analytic approaches. For patients 
who completed the treatment phase, the BOCF endpoint was 
defined as the last nonmissing observation, and for patients 
who discontinued early, the BOCF endpoint was defined as 
the baseline value.
For patients who discontinued trials early, drop-out 
reasons were classified as either treatment-related or 
non-treatment-related reasons. Treatment-related rea-
sons included “adverse events” and “lack of efficacy.” 
Nontreatment-related reasons included “entry criteria not 
met,” “protocol violation,” “lost to follow-up,” “subject 
decision,” (eg, work conflict, lack of transportation, change 
of location, or unwillingness to fill out questionnaires) and 
“physician decision (eg, investigator sites closing or patients 
deemed unreliable).”
As patients who discontinued due to non-treatment-
related reasons provide useful information in assessing 
the treatment effect, a modified BOCF (mBOCF) endpoint 
was defined as follows 1) for patients who completed the 
treatment phase, the BOCF endpoint was defined as the 
last nonmissing observation, or 2) for patients who discon-
tinued early due to treatment-related reasons (ie, adverse 
events [AEs] or lack of efficacy [LOE]), the BOCF endpoint 
was defined as the baseline value, and 3) for patients who  Patient Preference and Adherence 2010:4 13
Using BOcF to assess chronic pain Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
discontinued early due to nontreatment-related reasons 
(ie, reasons other than AEs or LOE), the BOCF endpoint 
was defined as the last nonmissing observation.
In the mBOCF approach, the change from baseline to the 
last observation (ie, the LOCF endpoint) was used for patients 
who discontinued due to nontreatment-related reasons and 
for completers, while a change of zero was used for patients 
who discontinued due to treatment-related reasons.
An additional BOCF approach, ie, aeBOCF was used 
where a change of zero was utilized for patients who discon-
tinued due to adverse events, while the change from baseline 
to the last observation (LOCF endpoint) was used for patients 
who discontinued due to any other reasons as well as for those 
who completed the studies.
For the mean change analyses using LOCF, BOCF, 
mBOCF, and aeBOCF approaches, an analysis of covari-
ance (ANCOVA) model including change from baseline-
to-endpoint baseline value, treatment, investigator, and 
treatment-by-investigator was used. Type III sum-of-squares 
for the least-squares mean (LS mean) was used to assess 
treatment difference.
In addition to mean change analysis, categorical analyses 
of response rate (defined as 30% reduction in BPI average 
pain, a change of 30% decrease is considered ‘moderately 
important’8) were also conducted using the LOCF, BOCF, 
mBOCF, and aeBOCF approaches. Fisher’s exact test was 
used to assess the treatment difference.
To assess the impact of different drop-out reasons on 
the patients’ efficacy outcomes, change from baseline to 
LOCF endpoint in BPI average pain was analyzed for the 
following disposition categories: 1) completions of 13-week 
treatment, 2) discontinuations due to adverse events, 
3) discontinuations due to lack of efficacy, and 4) discontinu-
ations due to reasons other than AEs or LOE.
Effect size was calculated using the treatment difference/
(standard error x the square root of N).
Patients with baseline and at least one postbaseline obser-
vation were included in all analyses. All tests were 2-sided at 
the 0.05 significance level. The term ‘significant’ indicates 
statistical significance throughout the manuscript.
Results
Patient disposition is shown in Table 1. Compared with the 
placebo-treated group, the duloxetine-treated group had 
significantly more discontinuations due to adverse events in 
both study 1 (P  0.05) and study 2 (P  0.01). In addition, 
in study 2, there was a significant difference (P  0.01) 
between the duloxetine-treated (72.7%) and placebo-treated 
(86.7%) groups in the number of patients who completed 
the study. In both studies, there were no differences between 
treatment groups for discontinuations due to subject decision, 
protocol violation, physician decision, lost to follow-up, lack 
of efficacy, and entry criteria not met.
In study 1, duloxetine was superior on the primary 
efficacy measure of mean change in the BPI average pain 
(Table 2), using the MMRM (-2.32), BOCF (-1.86), LOCF 
(-2.09), and mBOCF (-1.91), compared with placebo 
(MMRM [-1.50, P = 0.004], BOCF [-1.25, P = 0.019], 
LOCF [-1.45, P = 0.019], and mBOCF [-1.35, P = 0.041]). 
However, using the aeBOCF approach, there was no sig-
nificant difference between duloxetine [-1.94] and placebo 
[-1.46, P = 0.075]. In study 2, duloxetine was superior in the 
Table 1 Patient disposition
Study 1 Study 2
Placebo  
(N = 121)  
n (%)
Duloxetine  
60/120 mg/day  
(N = 115)  
n (%)
Placebo  
(N = 128)  
n (%)
Duloxetine  
60/120 mg/day   
(N = 128)  
n (%)
completers of the 13-week treatment 98 (81.0) 84 (73.0) 111 (86.7) 93 (72.7)**
Discontinuation for any reason 23 (19.0) 31 (27.0) 17 (13.3) 35 (27.3)**
  Adverse event 7 (5.8) 16 (13.9)* 7 (5.5) 24 (18.8)**
  Subject decision 10 (8.3) 11 (9.6) 2 (1.6) 4 (3.1)
  Protocol violation 2 (1.7) 2 (1.7) 2 (1.6) 3 (2.3)
  Physician decision 2 (1.7) 1 (0.9) 0 (0.0) 2 (1.6)
  Lost to follow-up 1 (0.8) 1 (0.9) 0 (0.0) 1 (0.8)
  Lack of efficacy 1 (0.8) 0 (0.0) 5 (3.9) 1 (0.8)
  entry criteria not met 0 (0.0) 0 (0.0) 1 (0.8) 0 (0.0)
Notes: *P  0.05 versus placebo; **P  0.01 versus placebo.
Abbreviations: n, number of patients in the specified category; N, total number of randomized patients. Patient Preference and Adherence 2010:4 14
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BPI average pain, using the MMRM (-2.72), BOCF (-2.23), 
LOCF (-2.51), mBOCF (-2.29), and aeBOCF (-2.29), 
compared with placebo (MMRM [–1.88, P  0.001], BOCF 
[–1.63, P = 0.013], LOCF [–1.72, P  0.001], mBOCF 
[–1.61, P = 0.005], and aeBOCF [–1.62, P = 0.005]). Effect 
size information is also provided.
There were no differences between the duloxetine and 
placebo groups in the percentage of responders in study 1 
(BOCF [45.9% versus 33.0%, P = 0.056], LOCF [53.2% 
versus 40.0%, P = 0.060], mBOCF [47.7% versus 37.4%, 
P = 0.137], and aeBOCF [48.6% versus 40.0%, P = 0.226]). 
In study 2, results of the 30% response rates (Table 3) 
showed a significantly greater percentage of responders 
in the duloxetine group than in the placebo group, using 
the BOCF (57% versus 42.5%, P = 0.031), LOCF (65.3% 
versus 44.1%, P  0.001), mBOCF (59.5% versus 42.5%, 
P = 0.008), and aeBOCF (59.5% versus 42.5%, P = 0.008) 
approaches.
Regardless of the disposition reasons, the treatment dif-
ference (not statistically significant) in the BPI average pain 
between the duloxetine-treated and placebo-treated groups 
occurred in the same direction as in completers (Table 4) 
Table 2 Mean change analysis of Brief Pain inventory average pain for all randomized patients in the 13-week treatment phase
Study Analysis Treatment groupa LS mean change (SE) Effect size P valueb
Study 1c MMRMd DLX 60/120 mg QD  
Placebo
–2.32 (0.22)  
–1.50 (0.21)
0.36 0.004
BOcF DLX 60/120 mg QD  
Placebo
–1.86 (0.20)  
–1.25 (0.20)
0.28 0.019
LOcF DLX 60/120 mg QD  
Placebo
–2.09 (0.21)  
–1.45 (0.21)
0.28 0.019
mBOcF DLX 60/120 mg QD  
Placebo
–1.91 (0.21)  
–1.35 (0.21)
0.25 0.041
aeBOcF DLX 60/120 mg QD  
Placebo
–1.94 (0.21)  
–1.46 (0.21)
0.21 0.075
Study 2e MMRMd DLX 60/120 mg QD  
Placebo
–2.72 (0.20)  
–1.88 (0.18)
0.41 0.001
BOcF DLX 60/120 mg QD  
Placebo
–2.23 (0.20)  
–1.63 (0.19)
0.28 0.013
LOcF DLX 60/120 mg QD  
Placebo
–2.51 (0.20)  
–1.72 (0.18)
0.39 0.001
mBOcF DLX 60/120 mg QD  
Placebo
–2.29 (0.20)  
–1.61 (0.19)
0.32 0.005
aeBOcF DLX 60/120 mg QD  
Placebo
–2.29 (0.20)  
–1.62 (0.19)
0.31 0.005
aStudy 1: n (DLX 60/120 QD) = 109, n (placebo) = 115.
Study 2: n (DLX 60/120 QD) = 121, n (placebo) = 127.
bP value comparison with placebo.
cBaseline mean (standard deviation): DLX 60/120 mg QD = 5.91 (1.61), placebo = 5.93 (1.67).
dPrimary efficacy analysis in study 1.
eBaseline mean (standard deviation): DLX 60/120 mg QD = 6.09 (1.38), placebo = 6.16 (1.26).
Abbreviations: aeBOcF, discontinuation due to adverse events only; BOcF, baseline observation carried forward; DLX, duloxetine; LOcF, last observation carried forward; 
LS Mean, least-squares mean; mBOCF, modified BOCF; MMRM, mixed-model repeated measures; QD, once daily; SE, standard error.
Table 3 Thirty percent response rate to Brief Pain inventory 
average pain
Study Analysis Treatment groupa Responderb  
n (%)
P valuec
Study 1 BOcF DLX 60/120 mg QD  
Placebo
50 (45.9)  
38 (33.0)
0.056
LOcF DLX 60/120 mg QD  
Placebo
58 (53.2)  
46 (40.0)
0.060
mBOcF DLX 60/120 mg QD  
Placebo
52 (47.7)  
43 (37.4)
0.137
aeBOcF DLX 60/120 mg QD  
Placebo
53 (48.6)  
46 (40.0)
0.226
Study 2 BOcF DLX 60/120 mg QD  
Placebo
69 (57.0)  
54 (42.5)
0.031
LOcF DLX 60/120 mg QD  
Placebo
79 (65.3)  
56 (44.1)
0.001
mBOcF DLX 60/120 mg QD  
Placebo
72 (59.5)  
54 (42.5)
0.008
aeBOcF DLX 60/120 mg QD  
Placebo
72 (59.5)  
54 (42.5)
0.008
aStudy 1: n (DLX 60/120 mg QD) = 109, n (placebo) = 115.
Study 2: n (DLX 60/120 mg QD) = 121, n (placebo) = 127.
bResponse was defined as at least a 30% reduction in BPI average pain.
cP value comparison with placebo.
Abbreviations: aeBOcF, discontinuation due to adverse events only; BOcF, baseline 
observation carried forward; BPi, Brief Pain inventory; DLX, duloxetine; LOcF, last 
observation carried forward; mBOCF, modified BOCF; MMRM, mixed-model repeated 
measures; N, number of patients in the specified category; QD, once daily. Patient Preference and Adherence 2010:4 15
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except for discontinuation due to reasons other than AEs 
or LOE in study 1.
Discussion
In both studies 1 and 2, duloxetine was superior to placebo on 
the primary efficacy measure (ie, change in BPI average pain) 
using the MMRM, BOCF, LOCF, and mBOCF approaches. 
Using aeBOCF, duloxetine did not separate from placebo in 
study 1, but did so in study 2. In study 2, the pattern seen in 
response rates (ie, 30% reduction in BPI average pain) was 
similar to that in the mean change analysis of BPI average 
pain ratings, with BOCF, LOCF, mBOCF, and aeBOCF 
approaches all demonstrating superiority of duloxetine over 
placebo. However, in study 1, none of the analytical methods 
demonstrated statistically significant differences between 
duloxetine and placebo in the 30% response rate of BPI 
average pain.
In patients who discontinued the trials, the drug-placebo 
treatment differences were generally in the same direction as 
in completers with the exception of discontinuation due to 
reasons other than AEs or LOE in study 1. However, none of 
these differences were statistically significant. While a con-
sistent treatment difference was observed in completers, and 
a general trend was also seen among drop-outs, a definitive 
characterization of the treatment effect in each of the discon-
tinuation categories was limited by the small sample sizes.
The BOCF approach does not consider changes observed 
in patients who discontinued due to reasons unrelated to treat-
ment. A previous publication of a multicenter, multi-study 
database reported factors associated with early study dis-
continuation9,10 and demonstrated that some of the variables 
associated with high loss to follow-up were age, female sex, 
African-American race, no previous enrollment in a study, 
and geography of sites other than the central United States. 
Additionally, in large multicenter trials, it is not uncommon 
to see a higher rate of discontinuation due to nontreatment-
related events in some countries compared with others, and 
this may be due to cultural differences among populations 
worldwide.
With the BOCF approach, the group of patients that are 
not taken into consideration because of discontinuation due 
to nontreatment-related reasons may actually have benefited 
from the studied treatment and may also benefit in a clinical 
practice setting, hence these patients should not be discounted 
in the analyses. In addition, even though the BOCF approach 
is sometimes perceived to be more conservative, this is 
not always the case, as demonstrated by the results from 
study 1 which showed a lower P value for the BOCF method 
(P = 0.019) versus the mBOCF (P = 0.041) and the aeBOCF 
(P = 0.075) methods.
The mBOCF approach is designed to take into consider-
ation the reasons for discontinuation by treating patients who 
discontinue due to treatment-related and nontreatment-related 
reasons differently. In the mBOCF approach, the change 
in mean pain scores from baseline to the last observation 
(LOCF endpoint) is used for patients who discontinue due 
to nontreatment-related reasons, while the baseline score 
(BOCF endpoint) is used for patients who discontinue due 
to treatment-related reasons. For patients who discontinued 
due to nontreatment-related reasons, their response may still 
reflect the true treatment response. Therefore, in the mBOCF 
approach, actual treatment outcomes from these patients 
were included in the assessment of the treatment difference 
between duloxetine and placebo. The aeBOCF approach 
was designed to take into consideration the reasons for 
discontinuation by treating patients who discontinue due to 
Table 4 Mean change analysis of BPi average pain (LOcF approach) for all randomized patients – by disposition status
Study 1 Study 2
Placebo Duloxetine  
60/120 mg/day
Placebo Duloxetine 
60/120 mg/day
n LS mean  
change (SE)
n LS mean  
change (SE)
n LS mean  
change (SE)
n LS mean 
change (SE)
completers 98 –1.51 (0.20) 84 –2.47 (0.22)*** 111 –2.02 (0.17) 92 –3.04 (0.19)***
Discontinuation  
due to
  Adverse events 4 0.85 (1.46) 13 –0.65 (1.06) 7 –0.88 (0.72) 20 –0.93 (0.45)
  Lack of efficacy 4 –0.79 (1.44) 3 –0.79 (1.30) 6 –0.36 (0.23) 1 –1.62 (0.54)
  Other reasons 9 –1.48 (0.95) 9 –0.49 (0.93) 3 0.07 (1.08) 8 –1.64 (0.69)
***P  0.001 versus placebo.
Abbreviations: BPI, Brief Pain Inventory; LOCF, last observation carried forward; LS, least squares; n, number of patients in the specified category; SE, standard error. Patient Preference and Adherence 2010:4
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treatment-related (adverse events) reasons only. The rationale 
for using aeBOCF is that if a drug is intolerable and leads to 
discontinuation, then it is considered not effective. By the 
similar argument, if a treatment is discontinued due to lack 
of efficacy, it should also be considered not effective.
Because patients who discontinue early from the clinical 
trials due to nontreatment-related reasons may make a rea-
sonable contribution when assessing treatment differences, 
consideration should be given to including these patients 
in the assessment of treatment effects, as in the mBOCF 
approach examined in these analyses. This would prevent 
biasing the outcome of a clinical trial due to patient drop-out 
for nontreatment-related reasons. It is a common and real 
challenge to handle early discontinuation in longitudinal 
clinical trials. It is therefore important to not rely solely 
on one single approach as the only statistical method to 
draw inferences. Different methods and sensitivity analy-
ses should be utilized to determine the robustness of the 
conclusions.
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